CALML3 and non-small cell lung carcinoma: The in-depth study demonstrates that CALML3-AS1 can inhibit BTNL9 transcription and expression through the recruitment of EZH2, giving rise to the counteraction of CALML3-AS1-mediated antitumor effects on NSCLC cells (61).